Business
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribersJoenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years
About this update from Pharming Group Nv
[{"type":"image","alt":"Pharming Group N.V.","displaySize":"","headline":null,"caption":"Pharming Group N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6VI_P53XoKPQr35Rp9bMIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e33000c1e8641d4ca14a349a419f6745","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patients and prescribers","length":156,"tagName":"p"}]},{"val":[{"type":"text","content":"Joenja® (leniolisib) third quarter revenue increased by 35% to US$15.1 million, compared to third quarter 2024, reflecting strong growth in patients on therapy ","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA granted priority review of sNDA for leniolisib for children aged 4 to 11 years with APDS with decision expected by January 2026","length":131,"tagName":"p"}]},{"val":[{"type":"text","content":"Third quarter operating profit increased by 285% to US$15.8 million, compared to US$4.1 million in the third quarter 2024","length":121,"tagName":"p"}]},{"val":[{"type":"text","content":"Generated US$32.0 million in cash flow from operations during the quarter and US$44.0 million year to date","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"2025 total revenue guidance raised to US$365 - US$375 million, up from prior US$335 - US$350 million","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Leverne Marsh appointed Chief Commercial Officer, effective January 1, 2026; Stephen Toor to step down as CCO at year-end and remain an advisor to the company","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Pharming to host a conference call today at 13:30 CET (7:30 am ET)","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1098,"olType":false},{"type":"text","content":"Leiden, the Netherlands, November 6, 2025: Pharming Group ...